Type 3 von Willebrand Disease in Pregnancy: A Systematic Literature Review

Mona M. Makhamreh; Stephanie L. Kass; Melissa L. Russo; Homa Ahmadzia; Huda B. Al-Kouatly

doi:10.1055/s-0039-1700541

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2021; 38(05): 436-448
DOI: 10.1055/s-0039-1700541

Review Article

Type 3 von Willebrand Disease in Pregnancy: A Systematic Literature Review

Mona M. Makhamreh

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

,

Stephanie L. Kass

²Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

,

Melissa L. Russo

³Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Women and Infants' Hospital of Rhode Island, The Warren Alpert Medical School of Brown University, Providence, Rhode Island

,

Homa Ahmadzia

⁴Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia

,

Huda B. Al-Kouatly

¹Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

› Institutsangaben

Abstract

Objective von Willebrand disease (VWD) is a hereditary bleeding disorder. Type 3 VWD is the most severe and rare phenotype that presents many challenges for management of pregnant women. The aim of this study was to review the maternal characteristics and complications in pregnant women with Type 3 VWD.

Study Design A systematic literature search was performed to include all publications that address Type 3 VWD in pregnancy.

Results Thirteen studies met the inclusion criteria. There were 28 pregnancies with Type 3 VWD in 17 women. All were diagnosed with Type 3 VWD prior to pregnancy. Concentrate treatment was administered before delivery for 19 pregnancies and postpartum for 26 pregnancies. Eight pregnancies required blood products postpartum. Primary postpartum hemorrhage (PPH) was reported in 48% (10/21) and secondary PPH was reported in 56% (5/9). Secondary PPH occurred between 7 and 22 days. No study reported hysterectomies, intensive care unit admissions, or maternal mortality. All 28 pregnancies resulted in 28 live births at term.

Conclusion Our review highlights the maternal outcomes in patients with Type 3 VWD and the different approaches in management during pregnancy and delivery. Despite prior knowledge of this bleeding disorder, PPH was still a significant complication.

Keywords

delivery - postpartum hemorrhage - pregnancy - Type 3 - von Willebrand disease

Volltext

Referenzen

References
1 Govorov I, Löfgren S, Chaireti R, Holmström M, Bremme K, Mints M. Postpartum hemorrhage in women with von Willebrand disease - a retrospective observational study. PLoS One 2016; 11 (10) e0164683
2 Caliezi C, Tsakiris DA, Behringer H, Kühne T, Marbet GA. Two consecutive pregnancies and deliveries in a patient with von Willebrand's disease type 3. Haemophilia 1998; 4 (06) 845-849
3 Cox Gill J. Diagnosis and treatment of von Willebrand disease. Hematol Oncol Clin North Am 2004; 18 (06) 1277-1299
4 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
5 Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost 2003; 1 (01) 190-192
6 Baronciani L, Cozzi G, Canciani MT. et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30 (03) 264-270
7 Munro MG, Critchley HOD, Broder MS, Fraser IS. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011; 113 (01) 3-13
8 Committee on Practice Bulletins-Obstetrics. Practice Bulletins No. 183: postpartum hemorrhage. Obstet Gynecol 2017; 130 (04) e168-e186
9 Chediak JR, Alban GM, Maxey B. von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. Am J Obstet Gynecol 1986; 155 (03) 618-624
10 Salman MC, Cil B, Esin S, Deren O. Late postpartum hemorrhage due to von Willebrand disease managed with uterine artery embolization. Obstet Gynecol 2008; 111 (2 Pt 2): 573-575
11 Sanhal C, Cirpan T. Successful management of a vaginal delivery and postpartum hemorrhage in a patient with von Willebrand disease type: case report. Turkiye Klinikleri J Gynecol Obst 2011; 21: 133-135
12 Martín-Salces M, Jiménez-Yuste V, Álvarez-Román MT, Rivas-Pollmar I, Rodríguez de la Rúa A. Management of delivery with FVIII/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodies. Thromb Haemost 2012; 108 (04) 796-798
13 Inocêncio G, Braga A, Azevedo S, Buchner G. Management of von Willebrand disease type 3 during pregnancy - 2 cases reports. Eur Rev Med Pharmacol Sci 2013; 17 (21) 2857-2859
14 Ososki R, Lambing A, Kuriakose P. Management of pregnancy in type 3 von Willebrand disease with additional platelet dysfunction. Haemophilia 2015; 21 (05) e412-e415
15 Zembala-Szczerba M, Huras H. von willebrand disease from the viewpoint of obstetrician - Case studies. Ginekologia i Poloznictwo 2015; 35: 88-94
16 Harrington P, Kyle P, Cutler J, Madan B. Successful management of multiple pregnancies in a family with varying severity of von Willebrand disease. Obstet Med 2018; 11 (04) 192-194
17 Scott M, Hay CRM, Elkhalifa S, Tower C, Cocker M, Thachil J. Management of pregnancy in type 3 von Willebrand disease with alloantibodies. Br J Haematol 2018; 182 (03) 440-442
18 Parker JW, James PD, Haley SL. Spinal anesthesia in 2 consecutive cesarean deliveries in a parturient with type 3 von Willebrand disease: a case report. A A Pract 2019; 12 (03) 79-81
19 Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14 (Suppl. 05) 47-53
20 Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351 (07) 683-694
21 Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105 (03) 314-321
22 Pasi KJ, Collins PW, Keeling DM. et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10 (03) 218-231
23 Berg CJ, Mackay AP, Qin C, Callaghan WM. Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005. Obstet Gynecol 2009; 113 (05) 1075-1081
24 Alexander J, Thomas P, Sanghera J. Treatments for secondary postpartum haemorrhage. Cochrane Database Syst Rev 2002; (01) CD002867
25 Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111 (04) 1236-1239
26 Chitty LS. Advances in the prenatal diagnosis of monogenic disorders. Prenat Diagn 2018; 38 (01) 3-5
27 Ash KM, Mibashan RS, Nicolaides KH. Diagnosis and treatment of feto-maternal hemorrhage in a fetus with homozygous von Willebrand's disease. Fetal Ther 1988; 3 (04) 189-191

Zusatzmaterial

Supplementary Material